An anti-VEGF single-domain antibody and a VHH chain thereof have been described. A coding sequence for coding the single-domain antibody or the VHH chain thereof, a corresponding expression vector, a host cell capable of expressing the single-domain antibody, and a production method for the single-domain antibody have been presented. The single-domain antibody can specifically recognize human VEGFA and will not cause cross reactions with VEGFB, VEGFC and VEGFD, thus having a good specificity. The single-domain antibody can further recognize VEGFAs of a human, a rat, a rabbit and a monkey, effectively blocks interactions between VEGFA and VEGFR2 and between VEGFA and VEGFR1, has an excellent inhibiting effect on angiogenesis, and has a good stability in a non-preparation condition.

In preferred embodiments the invention is directed to ocular compositions for the treatment of dry eye, methods for making such compositions, and suites comprising a plurality of different ocular compositions each having a defined composition. In preferred examples, the invention is directed to compositions comprising at least one natural oil, wherein a first member of the suite of compositions is effective in treating dry in in a first patient having a particular set of symptoms and a different second member of the suite of compositions is effective in treating dry in in a second patient having a different set of symptoms. The invention is also directed to methods of making and using the compositions, and to skin care compositions for use around the eye, such as the upper and lower eyelids having a lubricating, non-irritating base composition comprising at least one natural oil.

Methods and devices to identify contact lens wearers predisposed to contact lens discomfort are described. The methods and devices involve obtaining a tear film sample from a person and determining an amount of interleukin-17A present in the tear film sample.

In the present invention, among blood metabolites, amino acids, organic compounds and oxylipins that were statistically significantly differentiated from the control group, were selected from type 2 diabetes patients. Specifically, asparagine, aspartic acid, glutamic acid, cysteine, lysine, citric acid, and uric acid, and 12-oxo ETE, 15-oxo ETE, 9-oxo ODE, and 20-carboxy leukotriene B4, which are oxylipins, were confirmed to have cutoff values of AUC>0.7. In addition, the blood metabolites showed a significant difference between a DME patient group and a non-DME patient group, and thus were confirmed to be usable for accurate diagnosis of DME.

Labels and methods are provided for detecting deposits, including drusen, sub-retinal deposits, basal laminar and linear deposits, and the like. The labels can detect the presence, progression, or regression of hydroxyapatite, which can be indicative of the presence or the potential to develop such deposits. The labels can include a conjugate comprising a hydroxyapatite binding moiety and a label moiety, which can provide a detectable signal upon binding of the conjugate to hydroxyapatite. The labels and methods can be utilized to detect deposits in eye tissue, such as the retina, brain tissue, or the like. Methods are also provided for utilizing the present labels to predict or diagnose a neurodegenerative disease, including age-related macular degeneration. Accordingly, some methods can predict or diagnose age-related macular degeneration, including early signs or advanced forms thereof, based on the presence of hydroxyapatite in a tissue sample obtained from a subject.

The present invention provides for the use of hydroxyapatite-selective fluorescent dyes in combination with fluorescence lifetime imaging to detect any hydroxyapatite spherules or hydroxyapatite deposits in the retina tissue of a subject, including the peripheral or macula tissue, wherein the hydroxyapatite spherules or hydroxyapatite deposits initiate or support the growth of sub-RPE deposits and correlates with age-related macular degeneration and/or Alzheimer's disease.

A probe compound, contact lens containing bound probe, and method are disclosed for use in detecting analytes in basal tears on the surface of the eye of a subject. The probe composition preferably includes a hydrophilic portion, an analyte-sensitive portion and a fluorophore portion as well as a hydrophobic portion that allows binding to the contact lens material and optionally can modify the binding affinity of the fluorophore probe. The analyte-sensitive portion is configured to bind to a specific analyte in aqueous solution or to be quenched by the analyte. The fluorophore portion is configured to change an optical property of fluorescent light emitted in response to incident excitation light when the probe composition changes between a first state in which the analyte is not bound to the analyte-binding portion and a second state in which the analyte binds to the analyte-binding portion.

The present invention relates to a cell model for diseases associated with corneal neovascularization by using Epstein Barr virus (EBV)-infected human corneal epithelial cells (HCECs). Provided are a method for preparing a cell model for diseases associated with corneal neovascularization by using EBV-infected HCECs, the method including: infecting HCECs with EBV; culturing the infected HCECs; and determining whether the cultured HCECs are infected with EBV. In addition, provided is a method for screening diseases associated with corneal neovascularization prepared by the cell model for diseases associated with corneal neovascularization.

A method for diagnosing the development of a tissue injury in a subject comprising administering a sample of neoantibodies to the subject's tissue for the purpose of detecting the presence of neoepitopes bearing complement proteins.

The present application is directed to the use of a VEGF-C inhibitor, a VEGFR-2 inhibitor and/or a VEGFR-3 inhibitor as a prophylactic or therapeutic for the treatment of eye disorders such as a maculopathy and pathogenic ocular neovascularisation. The application is also directed to the use of a VEGF-C measurement from a biological sample from a mammalian subject as a predictive marker, a selected marker, a responsive marker or a tracking marker for a disease or condition selected from the group consisting of a maculopathy and pathogenic ocular neovascularization.